Treatment for multiple sclerosis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 30, 2005
filing date -
Mar 2, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions are provided for the treatment and/or diagnosis of disease caused by forms of multiple sclerosis that under-express and forms that over-express CD127. In specific examples, the methods for treating CD127-low MS comprise administering an effective amount of IL-7 or an effective amount of leukocytes treated with IL-7. Also provided are methods for treating CD127-low MS wherein leukocytes are induced to express at least one receptor, a subunit of which is CD127.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully